Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia
复制标题
DOI：
10.1080/10428190500525607
复制
发表时间：
2006-07-01
影响因子：
2.6
通讯作者：
Gobbi, Marco
中科院分区：
文献类型：
--
作者：
Miglino, Maurizio;Grasso, Raffaella;Gobbi, Marco
本研究的目的是阐明慢性髓性白血病（CML）克隆与正常造血之间的关系。对13例经伊马替尼治疗后达到完全细胞遗传学缓解（CCR）的女性患者进行了研究。尽管所有的研究患者都表现出X失活的多克隆模式，但通过巢式RT-PCR仍然可以检测到p210 BCR/ABL转录物。该研究还表明，13例研究患者中有9例存在p190转录本。需要更长的随访分析来阐明这些结果的预后价值。最近观察到，伊马替尼后多克隆缓解的CML患者可能出现克隆细胞遗传学异常，这表明缺乏BCR/ABL重排的肿瘤干细胞可能获得除费城染色体以外的进一步细胞遗传学改变。
The aim of this study was to elucidate the relationship between clonal and normal haematopoiesis in chronic myelogenous leukemia (CML). Thirteen female patients who reached complete cytogenetic response (CCR) after Imatinib(R) treatment were studied. Although all the study patients exhibited a polyclonal pattern of X inactivation, p210 BCR/ABL transcript remained detectable in all cases by nested RT-PCR. This study also demonstrated the presence of p190 transcript in nine out of 13 study patients. A longer follow-up analysis is needed to clarify the prognostic value of these results. The recent observation that clonal cytogenetic abnormalities may occur in CML patients in polyclonal remission after imatinib suggests that a neoplastic stem cell lacking BCR/ABL rearrangement may acquire further cytogenetic alterations other than Philadelphia chromosome.